Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Fibromyalgia patients taking GLP-1s have lower rates of opioid use, pain, fatigue, and malaise in a real-world patient data ...

MANY MEN STARTING GLP-1 medications like semaglutide or tirzepatide are trying to lose visceral fat. I’ve seen this in my ...

There’s no doubt that GLP-1 drugs like Ozempic have been revolutionary — although the benefits do sometimes come with some ...

Counterfeit GLP-1 weight-loss drugs are entering the U.S. from China, Turkey, and India, posing health risks due to potentially harmful ingredients.

Go noted that the improvements in the GLP-1 group occurred despite them having higher overall LDL and HbA1c levels at baseline than the those not on a GLP-1. A comparison of men and women suggested ...

Glucagon-like peptide-1 agonists are a class of medications historically used to treat type 2 diabetes and manage blood sugar. In recent years, some of these drugs have also been approved to treat ...

Compounded GLP-1s helped people continue treatment while brand-name GLP-1 injections were in shortage. But they’re not meant to be a long-term solution when FDA-approved options are available.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.

GLP-1 drugs mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite. Since obesity is a chronic condition, patients must plan to take the medications for ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find out why NVO stock is a buy.